<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bell's palsy: Treatment and prognosis in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bell's palsy: Treatment and prognosis in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bell's palsy: Treatment and prognosis in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ronthal, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patricia Greenstein, MB, BCh
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 12, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Idiopathic facial nerve palsy, also referred to as Bell's palsy, is the most common cause of spontaneous peripheral facial paralysis. A viral etiology (ie, activation of the herpes simplex virus) is suspected in most cases of Bell's palsy, although there is no established or widely available method of confirming a viral mechanism in clinical practice.
        </p>
        <p>
         This review will discuss the treatment and prognosis of Bell's palsy in adults. The pathogenesis, clinical features, and diagnosis of Bell's palsy in adults are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5281.html" rel="external">
          "Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults"
         </a>
         .)
        </p>
        <p>
         The clinical features, diagnosis, and management of facial palsy in children are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6217.html" rel="external">
          "Facial nerve palsy in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2641362362">
         <span class="h1">
          INITIAL TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mainstay of pharmacologic therapy for Bell's palsy or facial nerve palsy is early short-term oral glucocorticoid treatment. In severe acute cases, combining antiviral therapy with glucocorticoids may improve outcomes. Eye care is essential for patients with incomplete eye closure  (
         <a class="graphic graphic_algorithm graphicRef109357" href="/z/d/graphic/109357.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Glucocorticoids for all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         A short-term course of oral glucocorticoids is recommended for all patients with new-onset Bell's palsy [
         <a href="#rid1">
          1-4
         </a>
         ]. Treatment should ideally begin within three days of symptom onset, as this is the setting in which glucocorticoids have been studied and shown to be beneficial. We typically treat patients who are within seven days of symptom onset.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose
         </strong>
         – Our suggested regimen is
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (60 to 80 mg/day) for one week. Studied doses and regimens have varied; in the largest randomized trial, patients were treated with oral
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         60 mg daily for five days followed by a five-day taper by 10 mg per day [
         <a href="#rid5">
          5
         </a>
         ]. A one-week course without taper is simpler and delivers approximately the same total dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         – Glucocorticoids at these doses tend to be well tolerated, with no increase in major or minor adverse effects reported in randomized trials [
         <a href="#rid6">
          6
         </a>
         ]. The most common side effects are temporary sleep disruption, mood swings, high blood pressure, and dyspepsia. Caution is required in patients with diabetes due to the risk of hyperglycemia. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some clinicians routinely coadminister a proton pump inhibitor or H2 receptor antagonist, although the risk of gastric ulceration in this patient population is not well characterized and prevention is primarily supported in patients with additional risk factors (eg, concurrent use of nonsteroidal antiinflammatory drugs). (See
         <a class="medical medical_review" href="/z/d/html/35.html" rel="external">
          "NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – There is high-quality evidence from randomized trials that early glucocorticoids improve outcomes in patients with Bell's palsy [
         <a href="#rid1">
          1,6,7
         </a>
         ]. In a 2016 meta-analysis that included seven trials in 895 patients with Bell's palsy, glucocorticoids reduced the relative risk of incomplete recovery at 6 to 12 months by 37 percent compared with placebo or an inactive control (risk ratio [RR] 0.63, 95% CI 0.50-0.80) [
         <a href="#rid6">
          6
         </a>
         ]. In absolute terms, the risk difference for complete recovery was 11 percent favoring glucocorticoids (83 versus 72 percent; number needed to treat [NNT] to avoid one incomplete recovery, 10, 95% CI 6-20). The majority of trials enrolled patients within 72 hours of the onset of weakness.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1677149192">
         <span class="h2">
          Antiviral therapy for severe symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         It remains uncertain whether antiviral therapy adds benefit to glucocorticoids in patients with new-onset Bell's palsy, despite many trials and a good rationale. If there is a benefit, it is smaller and more incremental than what is achieved with glucocorticoids.
        </p>
        <p>
         Absent better data, we suggest coadministration of oral
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         or
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         along with glucocorticoids for patients with severe facial palsy  (
         <a class="graphic graphic_algorithm graphicRef109357" href="/z/d/graphic/109357.html" rel="external">
          algorithm 1
         </a>
         ), defined as House-Brackmann (H-B) grade IV or higher  (
         <a class="graphic graphic_table graphicRef70562" href="/z/d/graphic/70562.html" rel="external">
          table 1
         </a>
         ). This practice recognizes the high value of a possible, yet unproven, benefit of antiviral therapy in patients who are at higher risk for unfavorable outcomes, and the relatively low potential for harm of a short course of oral antiviral therapy. In patients with milder presentations, we use glucocorticoids alone, although some clinicians may reasonably choose to treat these patients as well. Antiviral therapy alone (without glucocorticoids) is not recommended [
         <a href="#rid1">
          1,3,4
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose
         </strong>
         – Our suggested regimen for antiviral therapy in patients with severe Bell's palsy is
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         1000 mg three times daily for one week [
         <a href="#rid5">
          5
         </a>
         ].
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
         400 mg five times daily for 10 days is an alternative to valacyclovir but is less convenient and has inferior bioavailability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          Valacyclovir
         </a>
         and
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         tend to be well tolerated. In the largest randomized trial, headache was numerically more common with valacyclovir than placebo [
         <a href="#rid5">
          5
         </a>
         ]. Agitation and hallucinations have been described with both agents, especially in older adults. Dose adjustments are required in patients with kidney impairment.
        </p>
        <p>
        </p>
        <p>
         <strong>
          Efficacy
         </strong>
         – Meta-analyses of randomized trials have found that antivirals alone are not effective for Bell's palsy [
         <a href="#rid6">
          6-10
         </a>
         ]. Conclusions on whether the combination of glucocorticoid plus antiviral therapy improves outcomes over glucocorticoids alone have been less consistent, and most have found a small benefits or no difference with wide confidence intervals [
         <a href="#rid7">
          7-11
         </a>
         ].
        </p>
        <p>
         In a meta-analysis of 18 trials in 2786 patients with Bell's palsy, treatment with glucocorticoids alone was associated with a reduced risk of unfavorable recovery compared with a control condition (RR 0.69, 95% CI 0.55-0.87), whereas treatment with antiviral agents alone was not (RR 1.14, 95% CI 0.80-1.62) [
         <a href="#rid7">
          7
         </a>
         ]. In pooled data from eight trials, the same meta-analysis found a trend towards a reduced risk of unfavorable recovery for combined antiviral and glucocorticoid treatment compared with glucocorticoid treatment alone, but the outcome just missed statistical significance (RR 0.75, 95% CI 0.56-1.0). In the two largest individual trials, glucocorticoid treatment alone was effective for Bell's palsy, while antiviral therapy showed no benefit when given alone or in combination with glucocorticoids [
         <a href="#rid5">
          5,12
         </a>
         ]. The absolute risk differences for complete recovery for combined therapy versus glucocorticoids alone were 3.4 percent (favoring combined therapy, 95% CI -4.6 to 11.3) in the largest trial (n = 829) [
         <a href="#rid5">
          5
         </a>
         ] and -3.3 percent (favoring glucocorticoids alone, 95% CI -9.7 to 2.7) in the second-largest trial (n = 551) [
         <a href="#rid12">
          12
         </a>
         ]. In comparison, the risk differences for glucocorticoids versus placebo were larger and statistically significant in both trials (15 percent [95% CI 8-21] and 13 percent [95% CI 7-19], respectively) [
         <a href="#rid1">
          1,5,12
         </a>
         ].
        </p>
        <p>
         A separate meta-analysis of three trials that compared glucocorticoid plus antiviral therapy with glucocorticoids alone found no benefit for motor recovery but reduced risk of late complications for patents with Bell’s palsy of varying degrees of severity [
         <a href="#rid11">
          11
         </a>
         ]. Based on data from the three retained trials (766 patients), the rates of incomplete recovery with combination therapy were similar to recovery with glucocorticoids alone (RR 0.81, 95% CI 0.38-1.74). However, the benefit of antivirals may have been masked by studies that included patients with mild cases and a favorable prognosis, diluting the benefit of the antivirals in patients with severe symptoms. In addition, in trials that reported on complications of severe palsy (two trials, 469 patients), combination therapy lowered the risk of motor synkinesis (eg, "crocodile tears") compared with glucocorticoids alone (RR 0.56, 95% CI 0.36-0.87).
        </p>
        <p class="headingAnchor" id="H1659030158">
         <span class="h2">
          Eye care to prevent corneal injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with Bell's palsy should be assessed for the completeness of eyelid closure. For those with incomplete closure (ie, sclera remains visible when the patient is asked to close the eye), meticulous eye care is required to prevent corneal injury [
         <a href="#rid2">
          2
         </a>
         ]. In addition to physical exposure due to eyelid weakness, the cornea is at increased risk for dryness and abrasion due to reduced tear production from the lacrimal gland, which is also innervated by the facial nerve.
        </p>
        <p>
        </p>
        <p>
         Eye care includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Waking hours
         </strong>
         – Patients should use artificial tear drops (liquid or gel) four times daily and up to hourly if needed. Gel formulations may cause transient blurry vision when applied.
         <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">
          Artificial tears
         </a>
         are available over the counter. Formulations with preservatives are safe for use four times a day, but preservative-free formulations are probably safer for more frequent application. (See
         <a class="medical medical_review" href="/z/d/html/6894.html" rel="external">
          "Dry eye disease", section on 'Artificial tears'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Protective glasses or goggles can be worn to physically protect the eye from external trauma. Some patients may prefer to tape the eyelid closed during the day to prevent exposure, using the same procedure as described for sleep. Patches are generally not recommended because there is a tendency for the eye to open under the patch and expose the cornea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with refractory eye dryness and exposure symptoms should be referred to ophthalmology for discussion of additional options such as a scleral lens, adhesive moisture chambers, temporary-suture tarsorrhaphy, and gold or platinum eyelid weighting [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="local">
          'Eyelid weights and tarsorrhaphy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          During sleep
         </strong>
         – Overnight and during naps, an ointment formulation of
         <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">
          artificial tears
         </a>
         should be applied to further protect the eye when it is most vulnerable. In addition, the eye can be carefully taped shut using a medical-grade waterproof transparent dressing or tape [
         <a href="#rid13">
          13
         </a>
         ]. The eye should be examined to make sure the eyelid remains completely closed under the dressing. Patching without taping is not generally recommended because the cornea remains exposed under the patch.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Other therapies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical therapy
         </strong>
         – We do not routinely prescribe physical therapy for newly diagnosed Bell's palsy, since most patients will recover function spontaneously. Nevertheless, physical therapy is often incorporated into multimodal interventions for patients with incomplete recovery. Limited data support the utility of facial exercise therapy for some patients with severe symptoms [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="local">
          'Role of physical and stimulation therapies'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical decompression (not recommended)
         </strong>
         – Some have advocated surgical decompression of the facial nerve via open middle cranial fossa craniectomy in severely affected patients with early motor nerve conduction studies (NCS) that show at least 90 percent degeneration of the facial nerve in the first 3 to 14 days after symptom onset, based on results of observational studies [
         <a href="#rid15">
          15
         </a>
         ]. However, this approach for patient selection has not been confirmed prospectively nor widely accepted [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Potential serious harms of middle cranial fossa surgery to decompress the labyrinthine segment of the bony facial canal include permanent unilateral hearing loss [
         <a href="#rid16">
          16,17
         </a>
         ]. Other risks include seizures, cerebrospinal fluid leak, and facial nerve injury [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A systematic review updated in 2021 found only two small randomized trials comparing surgery and nonsurgical control groups [
         <a href="#rid19">
          19
         </a>
         ]. The methodologic quality of both trials was very low, and there was no difference in outcome between the treatment groups in either trial. The authors concluded that there is insufficient evidence to decide whether surgery for Bell's palsy is beneficial. Similar conclusions were reached in an earlier systematic review from the American Academy of Neurology that identified four nonrandomized, prospective studies comparing patients treated with surgery versus no surgery [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3166490339">
         <span class="h1">
          FOLLOW-UP CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with acute Bell's palsy require follow-up to confirm improvement of facial weakness, monitor for ocular complications, and identify patients with incomplete recovery who may benefit from referral to a multidisciplinary facial nerve clinic [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H259718922">
         <span class="h2">
          New or worsening symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The weakness in patients with Bell's palsy typically evolves quickly to reach a nadir within one to two days of the onset of symptoms. The timing and pace of early recovery is variable and may wax and wane slightly, but the general course should be one of stability by three weeks and gradual improvement by two to three months.
        </p>
        <p>
         Worsening facial weakness beyond three weeks of presentation and/or development of any new neurologic symptoms (eg, diplopia, facial numbness, ataxia) should prompt reevaluation for alternative etiologies. Brain magnetic resonance imaging (MRI) with contrast is generally indicated, along with additional studies depending on the clinical presentation (eg, screening laboratories for underlying systemic disease or infection, lumbar puncture). (See
         <a class="medical medical_review" href="/z/d/html/5281.html" rel="external">
          "Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3332010400">
         <span class="h2">
          Incomplete recovery by three to four months
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with incomplete recovery of facial function following Bell's palsy can have varying degrees of facial weakness, hypertonia, and synkinesis, with functional problems related to incomplete eye closure, brow ptosis, and nasal valve collapse [
         <a href="#rid20">
          20
         </a>
         ]. Follow-up is essential  (
         <a class="graphic graphic_algorithm graphicRef109357" href="/z/d/graphic/109357.html" rel="external">
          algorithm 1
         </a>
         ) for eye care, psychologic support, and management of long-term sequelae. (See
         <a class="local">
          'Prognosis'
         </a>
         below and
         <a class="local">
          'Management of incomplete or aberrant recovery'
         </a>
         below.)
        </p>
        <p>
         A diagnosis of Bell's palsy is doubtful if some facial function, however small, has not returned within three to four months. If not previously performed, brain MRI and computed tomography (CT) with appropriate technique and slice thickness to image the full course of the facial nerve in the skull base and parotid gland should be obtained in patients with no recovery at this stage. Motor nerve conduction studies (NCS) and electromyography (EMG) can also be used to quantify the degree of axonal damage and assess for evidence of subclinical reinnervation. (See
         <a class="medical medical_review" href="/z/d/html/5281.html" rel="external">
          "Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults", section on 'Imaging studies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5281.html" rel="external">
          "Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults", section on 'Electrodiagnostic studies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2165042737">
         <span class="h1">
          PROGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H1920133515">
         <span class="h2">
          Recovery of facial nerve function
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis of Bell's palsy is very good. Approximately 70 percent of patients are expected to recover spontaneously by three to six months [
         <a href="#rid21">
          21
         </a>
         ], and rates of complete recovery increase to approximately 80 to 85 percent with glucocorticoid treatment [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="local">
          'Glucocorticoids for all patients'
         </a>
         above.)
        </p>
        <p>
         The main risk factor for incomplete recovery is the severity of weakness at presentation using the House-Brackmann (H-B) grading scale  (
         <a class="graphic graphic_table graphicRef70562" href="/z/d/graphic/70562.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid21">
          21-23
         </a>
         ]. Other grading systems (eg, the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fsunnybrook.ca%2Fuploads%2FFacialGradingSystem.pdf&amp;token=EeKzpC1vBGRVIFvyEGlS8JbKt6trOs7JBrbHSE88q8joEHbC2RsKXuqXxLPxIMjKjQagcFptyov0RGj4TbR4Lw%3D%3D&amp;TOPIC_ID=5286" target="_blank">
          Sunnybrook Facial Grading System
         </a>
         [
         <a href="#rid24">
          24
         </a>
         ]) are similar and sometimes favored [
         <a href="#rid25">
          25-28
         </a>
         ].
        </p>
        <p>
         In a contemporary study of over 1300 adults with Bell's palsy, 70 percent of patients presented with moderate weakness (H-B grade III or IV) and 30 percent had severe weakness (H-B grade ≥V) [
         <a href="#rid22">
          22
         </a>
         ]. On multivariable analysis, severe baseline weakness was associated with approximately 2.5 times the risk of unfavorable outcome, defined as H-B grade ≥III at six-month follow-up (odds ratio [OR] 2.62, 95% CI 1.93-3.57). In absolute terms, 84 percent of patients with moderate weakness improved to H-B grade II or better by six months, compared with 69 percent of those with severe weakness at presentation. Additional baseline clinical factors associated with worse outcome included age ≥40 years, diabetes, and uncontrolled hypertension.
        </p>
        <p>
         Recovery of facial paresis appears slightly worse in patients who develop the disease during pregnancy. A retrospective study of 77 patients with pregnancy-related Bell's palsy compared recovery outcome in pregnant patients with that of nonpregnant patients [
         <a href="#rid29">
          29
         </a>
         ]. All patients in all groups with incomplete paralysis ultimately recovered satisfactory function. However, more pregnant patients developed complete paralysis (65 versus 50 percent for nonpregnant patients). Pregnant patients (as well as nonpregnant patients) with complete paralysis are less likely to recover satisfactory function than the other groups (52 versus 77 to 88 percent). The fact that pregnant patients are less likely to receive treatment may also contribute to an apparent poorer prognosis [
         <a href="#rid30">
          30,31
         </a>
         ].
        </p>
        <p>
         Nerve conduction studies (NCS) and electromyography (EMG) of the facial nerve can be used to help predict recovery in patients with severe weakness. (See
         <a class="medical medical_review" href="/z/d/html/5281.html" rel="external">
          "Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults", section on 'Electrodiagnostic studies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H799340527">
         <span class="h2">
          Complications of regeneration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Synkinesia and contractures of the face develop in approximately 15 percent of patients as a late complication of Bell's palsy due to disorganized and misdirected nerve regrowth [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Synkinesia refers to involuntary contraction or twitching of part of the facial musculature upon voluntary facial movement. For example, twitching of the angle of the mouth may occur when the patient blinks forcefully, or contracture of the orbicular oculi and narrowing of the palpebral fissure may occur with smiling. Nonmotor synkinesias can also develop due to misdirected autonomic fibers. In the syndrome of gustatory tearing or "crocodile tears," a salivary stimulus results in excess lacrimation. Less commonly, salivation causes facial sweating.
        </p>
        <p>
         Most synkinesia after Bell's palsy is mild and may not be noticed by the affected individual. More severe or bothersome synkinesia can be treated with botulinum toxin injections. (See
         <a class="local">
          'Botulinum toxin for synkinesias'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1800951225">
         <span class="h2">
          Psychological impact
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic facial weakness has both physical and psychological implications, with negative effects on socialization and emotional well-being. Facial disfigurement can cause psychosocial distress resulting in decreased quality of life and increased risk for depression and anxiety [
         <a href="#rid32">
          32-34
         </a>
         ]. Patients may suffer from poor self-confidence, phobic avoidance, and social isolation [
         <a href="#rid35">
          35
         </a>
         ]. Of 22,594 patients surveyed at the Edinburgh facial palsy clinic, one-half exhibited a considerable degree of psychological distress and restriction in social activities as a consequence of their facial palsy [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Psychosocial distress may also occur in some patients without severe facial weakness. In a meta-analysis of 23 studies reporting quality-of-life outcomes among 3746 patients with peripheral facial weakness, the psychological burden was only weakly correlated with the severity of facial weakness (0.36, 95% CI 0.24-0.46) [
         <a href="#rid37">
          37
         </a>
         ]. Other factors may include older age, female sex, and higher depression or anxiety scores on testing [
         <a href="#rid38">
          38-40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1368800340">
         <span class="h2">
          Risk of recurrent Bell's palsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent attacks of Bell's palsy on either the ipsilateral or contralateral side have been observed in 7 to 15 percent of patients [
         <a href="#rid41">
          41-44
         </a>
         ]. In one of the larger natural history studies with prolonged follow-up, the mean time to recurrence was approximately 10 years [
         <a href="#rid44">
          44
         </a>
         ]. Due to the rarity, alternative etiologies should also be considered at the time of recurrence. In one referral center series, one-quarter of 53 patients with recurrent Bell's palsy were found to have an alternative etiology, most commonly Melkersson-Rosenthal syndrome, neurosarcoidosis, or facial nerve schwannoma [
         <a href="#rid45">
          45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5281.html" rel="external">
          "Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults", section on 'Melkersson-Rosenthal syndrome'
         </a>
         .)
        </p>
        <p>
         Pregnancy may be a risk factor for recurrence of Bell's palsy [
         <a href="#rid46">
          46
         </a>
         ]. Additional risk factors are not well defined. Some patients with recurrent attacks have a family history of multiple attacks, suggesting a genetic predisposition to Bell's palsy. (See
         <a class="medical medical_review" href="/z/d/html/5281.html" rel="external">
          "Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H830882947">
         <span class="h1">
          MANAGEMENT OF INCOMPLETE OR ABERRANT RECOVERY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with incomplete or aberrant recovery may benefit from a multimodality approach and referral to facial plastic and reconstructive surgery. Patients with persistent severe deficits may be candidates for chemodenervation with botulinum toxin injections and selective surgical procedures to improve function and appearance [
         <a href="#rid13">
          13,20,47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2267421525">
         <span class="h2">
          Botulinum toxin for synkinesias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Botulinum toxin injections may benefit patients with synkinesis, facial spasm, or hyperlacrimation ("crocodile tears") [
         <a href="#rid20">
          20,48,49
         </a>
         ].
        </p>
        <p>
         In facial synkinesis, botulinum toxin is used to selectively inhibit muscle contractility. Common facial muscle targets include the orbicularis oculi, depressor anguli oris, depressor labii inferioris, mentalis, and platysma [
         <a href="#rid50">
          50
         </a>
         ]. Some patients develop compensatory hyperfunction and hypertrophy in the contralateral side of the face that may also be targeted with botulinum toxin to improve symmetry.
        </p>
        <p class="headingAnchor" id="H513732774">
         <span class="h2">
          Eyelid weights and tarsorrhaphy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Insertion of a gold or platinum weight into the upper eyelid is the most common dynamic technique used to treat persistent severe lagophthalmos after Bell's palsy. Platinum weights are smaller than gold implants and may be less allergenic and prone to extrusion [
         <a href="#rid13">
          13
         </a>
         ]. Lower eyelid lag may also need to be addressed in patients with severe paralysis by suspension or augmentation techniques. Palpebral springs may be an option in patients who fail eyelid weights.
        </p>
        <p class="headingAnchor" id="H2130588224">
         <span class="h2">
          Cosmetic procedures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Brow ptosis due to prior Bell's palsy can exacerbate lagophthalmos and contribute to poor cosmetic recovery. Correction via brow lift procedures may enhance facial symmetry and cosmetic appearance [
         <a href="#rid20">
          20
         </a>
         ]. Cosmetic and functional improvement may be possible with facial reanimation surgery, although it is rarely done [
         <a href="#rid20">
          20,51-53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2621555106">
         <span class="h2">
          Role of physical and stimulation therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Physical therapy encompasses a range of interventions for Bell's palsy, including but not limited to facial exercises, mime therapy, massage, electrical stimulation, acupuncture, heat therapy, and biofeedback. Although not supported by high-quality data, physical therapy is an integral component of most multidisciplinary care plans in patients with severe weakness and incomplete recovery [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         A systematic review of physical therapy for Bell's palsy identified 12 controlled trials with 872 participants, including four trials of electrical stimulation, three of exercises, and five of acupuncture compared or combined with another form of physical therapy [
         <a href="#rid54">
          54
         </a>
         ]. Facial exercises did not reduce the proportion of patients with incomplete recovery at six months. One low-quality trial reported that facial exercises reduced the rate of synkinesis at three months. Another low-quality trial of 34 subjects with persistent facial palsy that lasted more than nine months found that exercises (mime therapy) led to some improvement in facial function at one year. Similarly, studies of electrical stimulation or acupuncture have failed to find significant benefit or harm. However, a subsequent trial has reported benefit of electrical simulation on facial nerve disability scores and electrophysiologic outcomes for some patients with Bell’s palsy [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1147324739">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112593.html" rel="external">
          "Society guideline links: Bell's palsy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15818.html" rel="external">
          "Patient education: Bell's palsy (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/722.html" rel="external">
          "Patient education: Bell's palsy (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and pathogenesis
         </strong>
         – Bell's palsy, also referred to as idiopathic facial nerve palsy or facial nerve palsy of suspected viral etiology, is the most common cause of acute spontaneous peripheral facial paralysis. Inflammation, nerve edema, and herpes simplex virus (HSV) reactivation are thought to play a role in pathogenesis in most patients. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Glucocorticoids for all patients
         </strong>
         – For all patients with new-onset Bell's palsy, we recommend oral glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Early treatment (eg, within three days of symptom onset) increases the rate of complete recovery. We typically treat patients who are within seven days of symptom onset. Our suggested regimen is
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (60 to 80 mg/day) for one week without a taper. (See
         <a class="local">
          'Glucocorticoids for all patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antiviral therapy for patients with severe palsy
         </strong>
         – For patients with severe facial palsy at presentation, defined as House-Brackmann grade IV or higher  (
         <a class="graphic graphic_table graphicRef70562" href="/z/d/graphic/70562.html" rel="external">
          table 1
         </a>
         ), we suggest adjunctive oral antiviral therapy rather than glucocorticoids alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The benefit of antiviral therapy for recovery is uncertain, but treatment appears to be safe in most people. The usual regimen is
         <a class="drug drug_general" data-topicid="10034" href="/z/d/drug information/10034.html" rel="external">
          valacyclovir
         </a>
         1000 mg three times daily for one week.
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          Acyclovir
         </a>
         (400 mg five times daily for 10 days) is an alternative to valacyclovir but is less convenient and has inferior bioavailability. (See
         <a class="local">
          'Antiviral therapy for severe symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prevent corneal injury
         </strong>
         – We assess all patients for the completeness of eye closure. For those with incomplete closure, we advise meticulous eye care to prevent corneal injury (see
         <a class="local">
          'Eye care to prevent corneal injury'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Waking hours
         </strong>
         – Apply
         <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">
          artificial tears
         </a>
         (liquid or gel) four times daily and up to hourly if needed and eye protection (eg, glasses or goggles) to protect from trauma.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          During sleep
         </strong>
         – Apply
         <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">
          artificial tears
         </a>
         ointment and tape the eyelid shut. We advise
         <strong>
          not
         </strong>
         using an eye patch without taping as this leaves the cornea exposed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We instruct patients to monitor for and report any ocular complications (eg, corneal abrasion, foreign body injury).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up management
         </strong>
         – For patients whose symptoms worsen &gt;3 weeks from symptom onset and for those with incomplete recovery at three to four months, we advise further evaluation to exclude other causes of facial palsy and to identify opportunities for additional treatment. (See
         <a class="local">
          'Follow-up care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with incomplete or aberrant recovery may be candidates for botulinum toxin injections or selective surgical procedures to improve function and appearance. (See
         <a class="local">
          'Management of incomplete or aberrant recovery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The prognosis of Bell's palsy is very good. Approximately 80 to 85 percent experience a full recovery of facial nerve function by six months. The main risk factor for incomplete recovery is severity of weakness at the time of presentation  (
         <a class="graphic graphic_table graphicRef70562" href="/z/d/graphic/70562.html" rel="external">
          table 1
         </a>
         ). Synkinesias due to aberrant or disorganized nerve regrowth affect approximately 15 percent of patients. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Gronseth GS, Paduga R, American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2012; 79:2209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baugh RF, Basura GJ, Ishii LE, et al. Clinical practice guideline: Bell's palsy. Otolaryngol Head Neck Surg 2013; 149:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz SR, Jones SL, Getchius TS, Gronseth GS. Reconciling the clinical practice guidelines on Bell's palsy from the AAO-HNSF and the AAN. Otolaryngol Head Neck Surg 2014; 150:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Almeida JR, Guyatt GH, Sud S, et al. Management of Bell palsy: clinical practice guideline. CMAJ 2014; 186:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engström M, Berg T, Stjernquist-Desatnik A, et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2008; 7:993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madhok VB, Gagyor I, Daly F, et al. Corticosteroids for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2016; 7:CD001942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Almeida JR, Al Khabori M, Guyatt GH, et al. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. JAMA 2009; 302:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quant EC, Jeste SS, Muni RH, et al. The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis. BMJ 2009; 339:b3354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Veen EL, Rovers MM, de Ru JA, van der Heijden GJ. A small effect of adding antiviral agents in treating patients with severe Bell palsy. Otolaryngol Head Neck Surg 2012; 146:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turgeon RD, Wilby KJ, Ensom MH. Antiviral treatment of Bell's palsy based on baseline severity: a systematic review and meta-analysis. Am J Med 2015; 128:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gagyor I, Madhok VB, Daly F, Sullivan F. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2019; 9:CD001869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 2007; 357:1598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacIntosh PW, Fay AM. Update on the ophthalmic management of facial paralysis. Surv Ophthalmol 2019; 64:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan AJ, Szczepura A, Palmer S, et al. Physical therapy for facial nerve paralysis (Bell's palsy): An updated and extended systematic review of the evidence for facial exercise therapy. Clin Rehabil 2022; 36:1424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gantz BJ, Rubinstein JT, Gidley P, Woodworth GG. Surgical management of Bell's palsy. Laryngoscope 1999; 109:1177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grogan PM, Gronseth GS. Practice parameter: Steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:830.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAllister K, Walker D, Donnan PT, Swan I. Surgical interventions for the early management of Bell's palsy. Cochrane Database Syst Rev 2013; :CD007468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland NJ, Weiner GM. Recent developments in Bell's palsy. BMJ 2004; 329:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menchetti I, McAllister K, Walker D, Donnan PT. Surgical interventions for the early management of Bell's palsy. Cochrane Database Syst Rev 2021; 1:CD007468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eviston TJ, Croxson GR, Kennedy PG, et al. Bell's palsy: aetiology, clinical features and multidisciplinary care. J Neurol Neurosurg Psychiatry 2015; 86:1356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peitersen E. The natural history of Bell's palsy. Am J Otol 1982; 4:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoo MC, Soh Y, Chon J, et al. Evaluation of Factors Associated With Favorable Outcomes in Adults With Bell Palsy. JAMA Otolaryngol Head Neck Surg 2020; 146:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg 1985; 93:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross BG, Fradet G, Nedzelski JM. Development of a sensitive clinical facial grading system. Otolaryngol Head Neck Surg 1996; 114:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chee GH, Nedzelski JM. Facial nerve grading systems. Facial Plast Surg 2000; 16:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg T, Jonsson L, Engström M. Agreement between the Sunnybrook, House-Brackmann, and Yanagihara facial nerve grading systems in Bell's palsy. Otol Neurotol 2004; 25:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coulson SE, Croxson GR, Adams RD, O'Dwyer NJ. Reliability of the "Sydney," "Sunnybrook," and "House Brackmann" facial grading systems to assess voluntary movement and synkinesis after facial nerve paralysis. Otolaryngol Head Neck Surg 2005; 132:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsk E, Bylund N, Jonsson L, et al. Prediction of nonrecovery in Bell's palsy using Sunnybrook grading. Laryngoscope 2012; 122:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillman GS, Schaitkin BM, May M, Klein SR. Bell's palsy in pregnancy: a study of recovery outcomes. Otolaryngol Head Neck Surg 2002; 126:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vrabec JT, Isaacson B, Van Hook JW. Bell's palsy and pregnancy. Otolaryngol Head Neck Surg 2007; 137:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen Y, Lavie O, Granovsky-Grisaru S, et al. Bell palsy complicating pregnancy: a review. Obstet Gynecol Surv 2000; 55:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SY, Kong IG, Oh DJ, Choi HG. Increased risk of depression in Bell's palsy: Two longitudinal follow-up studies using a national sample cohort. J Affect Disord 2019; 251:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fu L, Bundy C, Sadiq SA. Psychological distress in people with disfigurement from facial palsy. Eye (Lond) 2011; 25:1322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker DT, Hallam MJ, Ni Mhurchadha S, et al. The psychosocial impact of facial palsy: our experience in one hundred and twenty six patients. Clin Otolaryngol 2012; 37:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nellis JC, Ishii M, Byrne PJ, et al. Association Among Facial Paralysis, Depression, and Quality of Life in Facial Plastic Surgery Patients. JAMA Facial Plast Surg 2017; 19:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weir AM, Pentland B, Murray J. Bell's palsy: The effect on self image, mood state and social activity. Clin Rehabil 1993; 7:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruins TE, van Veen MM, Werker PMN, et al. Associations Between Clinician-Graded Facial Function and Patient-Reported Quality of Life in Adults With Peripheral Facial Palsy: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg 2021; 147:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruins TE, van Veen MM, Mooibroek-Leeuwerke T, et al. Association of Socioeconomic, Personality, and Mental Health Factors With Health-Related Quality of Life in Patients With Facial Palsy. JAMA Otolaryngol Head Neck Surg 2020; 146:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tavares-Brito J, van Veen MM, Dusseldorp JR, et al. Facial Palsy-Specific Quality of Life in 920 Patients: Correlation With Clinician-Graded Severity and Predicting Factors. Laryngoscope 2019; 129:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleiss IJ, Hohman MH, Susarla SM, et al. Health-related quality of life in 794 patients with a peripheral facial palsy using the FaCE Scale: a retrospective cohort study. Clin Otolaryngol 2015; 40:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CAWTHORNE T, HAYNES DR. Facial palsy. Br Med J 1956; 2:1197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boddie HG. Recurrent Bell's palsy. J Laryngol Otol 1972; 86:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hallmo P, Elverland HH, Mair IW. Recurrent facial palsy. Arch Otorhinolaryngol 1983; 237:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pitts DB, Adour KK, Hilsinger RL Jr. Recurrent Bell's palsy: analysis of 140 patients. Laryngoscope 1988; 98:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chweya CM, Anzalone CL, Driscoll CLW, et al. For Whom the Bell's Toll: Recurrent Facial Nerve Paralysis, A Retrospective Study and Systematic Review of the Literature. Otol Neurotol 2019; 40:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGregor JA, Guberman A, Amer J, Goodlin R. Idiopathic facial nerve paralysis (Bell's palsy) in late pregnancy and the early puerperium. Obstet Gynecol 1987; 69:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadlock TA, Greenfield LJ, Wernick-Robinson M, Cheney ML. Multimodality approach to management of the paralyzed face. Laryngoscope 2006; 116:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito H, Ito H, Nakano S, Kusaka H. Low-dose subcutaneous injection of botulinum toxin type A for facial synkinesis and hyperlacrimation. Acta Neurol Scand 2007; 115:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nava-Castañeda A, Tovilla-Canales JL, Boullosa V, et al. Duration of botulinum toxin effect in the treatment of crocodile tears. Ophthal Plast Reconstr Surg 2006; 22:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markey JD, Loyo M. Latest advances in the management of facial synkinesis. Curr Opin Otolaryngol Head Neck Surg 2017; 25:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas RS, Gausas RE. A systematic comprehensive approach to management of irreversible facial paralysis. Facial Plast Surg 2003; 19:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labbé D, Bénateau H, Bardot J. [Surgical procedures for labial reanimation in facial paralysis]. Ann Chir Plast Esthet 2002; 47:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jowett N, Hadlock TA. Contemporary management of Bell palsy. Facial Plast Surg 2015; 31:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teixeira LJ, Valbuza JS, Prado GF. Physical therapy for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2011; :CD006283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuncay F, Borman P, Taşer B, et al. Role of electrical stimulation added to conventional therapy in patients with idiopathic facial (Bell) palsy. Am J Phys Med Rehabil 2015; 94:222.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5286 Version 48.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23136264" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24189771" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical practice guideline: Bell's palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24789656" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Reconciling the clinical practice guidelines on Bell's palsy from the AAO-HNSF and the AAN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24934895" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Management of Bell palsy: clinical practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18849193" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27428352" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Corticosteroids for Bell's palsy (idiopathic facial paralysis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19724046" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19736282" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22217913" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A small effect of adding antiviral agents in treating patients with severe Bell palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25554380" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Antiviral treatment of Bell's palsy based on baseline severity: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31486071" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Antiviral treatment for Bell's palsy (idiopathic facial paralysis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17942873" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Early treatment with prednisolone or acyclovir in Bell's palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29886125" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Update on the ophthalmic management of facial paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35787015" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Physical therapy for facial nerve paralysis (Bell's palsy): An updated and extended systematic review of the evidence for facial exercise therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10443817" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Surgical management of Bell's palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11294918" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Practice parameter: Steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24132718" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Surgical interventions for the early management of Bell's palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15345630" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Recent developments in Bell's palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33496980" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Surgical interventions for the early management of Bell's palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25857657" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Bell's palsy: aetiology, clinical features and multidisciplinary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7148998" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The natural history of Bell's palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31971554" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Evaluation of Factors Associated With Favorable Outcomes in Adults With Bell Palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3921901" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Facial nerve grading system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8649870" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Development of a sensitive clinical facial grading system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11460297" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Facial nerve grading systems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15547437" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Agreement between the Sunnybrook, House-Brackmann, and Yanagihara facial nerve grading systems in Bell's palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15806042" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Reliability of the "Sydney," "Sunnybrook," and "House Brackmann" facial grading systems to assess voluntary movement and synkinesis after facial nerve paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22374870" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Prediction of nonrecovery in Bell's palsy using Sunnybrook grading.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11821761" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Bell's palsy in pregnancy: a study of recovery outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18036410" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Bell's palsy and pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10713984" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Bell palsy complicating pregnancy: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30933749" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Increased risk of depression in Bell's palsy: Two longitudinal follow-up studies using a national sample cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21720412" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Psychological distress in people with disfigurement from facial palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22994846" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The psychosocial impact of facial palsy: our experience in one hundred and twenty six patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27930763" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Association Among Facial Paralysis, Depression, and Quality of Life in Facial Plastic Surgery Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Bell's palsy: The effect on self image, mood state and social activity
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34196663" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Associations Between Clinician-Graded Facial Function and Patient-Reported Quality of Life in Adults With Peripheral Facial Palsy: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32053138" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Association of Socioeconomic, Personality, and Mental Health Factors With Health-Related Quality of Life in Patients With Facial Palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30208215" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Facial Palsy-Specific Quality of Life in 920 Patients: Correlation With Clinician-Graded Severity and Predicting Factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25858429" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Health-related quality of life in 794 patients with a peripheral facial palsy using the FaCE Scale: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13364414" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Facial palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4636813" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Recurrent Bell's palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6847518" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Recurrent facial palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3362016" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Recurrent Bell's palsy: analysis of 140 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30870370" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : For Whom the Bell's Toll: Recurrent Facial Nerve Paralysis, A Retrospective Study and Systematic Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3808518" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Idiopathic facial nerve paralysis (Bell's palsy) in late pregnancy and the early puerperium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16885741" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Multimodality approach to management of the paralyzed face.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17376126" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Low-dose subcutaneous injection of botulinum toxin type A for facial synkinesis and hyperlacrimation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17117101" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Duration of botulinum toxin effect in the treatment of crocodile tears.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28604403" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Latest advances in the management of facial synkinesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12739186" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A systematic comprehensive approach to management of irreversible facial paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12449881" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : [Surgical procedures for labial reanimation in facial paralysis].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25958893" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Contemporary management of Bell palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22161401" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Physical therapy for Bell's palsy (idiopathic facial paralysis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25171666" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Role of electrical stimulation added to conventional therapy in patients with idiopathic facial (Bell) palsy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
